 |
|
Positron Emission Tomography (PET) Can Identify Effectiveness of Chemotherapy Early in High-Risk Breast Cancer Patients
July 27, 2005Predicting Therapy Response Offers Possibility for Improved, Individualized Patient Care
RESTON, Va.-The effectiveness of chemotherapy in patients with advanced breast cancer can be evaluated earlier by using 18F-FDG positron emission tomography (PET) imaging over other conventional imaging procedures, according to an article in the July issue of the Society of Nuclear Medicine's Journal of Nuclear Medicine.
PET imaging performed at baseline and after the initiation of treatment "allowed prediction of response as early as after the first cycle of chemotherapy," said Norbert Avril, M.D., chief of the division of nuclear medicine at the University of Pittsburgh Medical Center, Pittsburgh, Pa. Conventional imaging procedures, such as computed tomography (CT), magnetic resonance imaging (MRI), plain film radiography and ultrasound, do not reliably predict therapy response early in the course of treatment, explained the co-author of "Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET."
Metastatic breast cancer is the most advanced stage of breast cancer. Cancer cells have spread past the breast and underarm lymph nodes to other areas of the body, continuing to grow, multiply and possibly spread to other regions of the body. Chemotherapy, which uses drugs to stop the growth of cancer cells, either by killing the cells or stopping the cells from dividing, is typically used with patients. At this advanced stage of the disease, the aim of treatment is to improve survival and quality of life, since the disease is generally not curable, said Avril. It's essential to identify those individuals who don't respond to chemotherapy early "to avoid ineffective therapies and unnecessary side effects," he noted. This ability to individualize treatment gives patients and physicians options not previously available, added Avril, indicating that additional studies are needed to determine how to use 18F-FDG PET in a clinical setting.
PET is a powerful medical imaging procedure that noninvasively demonstrates the function of organs and other tissues. It is used primarily as a diagnostic tool in cardiology, neurology, oncology and many other medical specialties. To image cancer, a radiopharmaceutical such as fluorodeoxyglucose (FDG), which includes both sugar (metabolized at a higher rate by cancer cells) and a radionuclide, is injected into the patient. Because cancer cells metabolize sugar at higher rates than normal cells, the radiopharmaceutical is drawn in higher concentrations to cancerous areas. The PET scan shows where the radiopharmaceutical is by tracking the gamma ray signals given off by the radionuclides.
Avril co-wrote "Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET" with Joerg Dose Schwarz, M.D., Michael Bader, M.D., Gabriele Hemminger, M.D., and Fritz Janicke, M.D., department of gynecology, and Lars Jenicke, M.D., department of nuclear medicine, all at the University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Society of Nuclear Medicine
Metastatic breast cancer is the most advanced stage of breast cancer. Cancer cells have spread past the breast and underarm lymph nodes to other areas of the body, continuing to grow, multiply and possibly spread to other regions of the body. Chemotherapy, which uses drugs to stop the growth of cancer cells, either by killing the cells or stopping the cells from dividing, is typically used with patients. At this advanced stage of the disease, the aim of treatment is to improve survival and quality of life, since the disease is generally not curable, said Avril. It's essential to identify those individuals who don't respond to chemotherapy early "to avoid ineffective therapies and unnecessary side effects," he noted. This ability to individualize treatment gives patients and physicians options not previously available, added Avril, indicating that additional studies are needed to determine how to use 18F-FDG PET in a clinical setting.
PET is a powerful medical imaging procedure that noninvasively demonstrates the function of organs and other tissues. It is used primarily as a diagnostic tool in cardiology, neurology, oncology and many other medical specialties. To image cancer, a radiopharmaceutical such as fluorodeoxyglucose (FDG), which includes both sugar (metabolized at a higher rate by cancer cells) and a radionuclide, is injected into the patient. Because cancer cells metabolize sugar at higher rates than normal cells, the radiopharmaceutical is drawn in higher concentrations to cancerous areas. The PET scan shows where the radiopharmaceutical is by tracking the gamma ray signals given off by the radionuclides.
Avril co-wrote "Early Prediction of Response to Chemotherapy in Metastatic Breast Cancer Using Sequential 18F-FDG PET" with Joerg Dose Schwarz, M.D., Michael Bader, M.D., Gabriele Hemminger, M.D., and Fritz Janicke, M.D., department of gynecology, and Lars Jenicke, M.D., department of nuclear medicine, all at the University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Society of Nuclear Medicine
Positron Emission Tomography Current Events and Positron Emission Tomography News RSSScripps research scientists find new link between insulin and core body temperature
A team led by scientists at The Scripps Research Institute have discovered a direct link between insulin-a hormone long associated with metabolism and metabolic disorders such as diabetes-and core body temperature.
Neuroimaging provides insights into new treatment options for Alzheimer's disease
With about 35 million people around the world suffering from Alzheimer's disease (AD) by the year 2010 and an expectation that these numbers will double every twenty years with approximately 115 million cases by 2050, pressure on healthcare systems worldwide will be intense.
Loss of tumor supressor gene essential to transforming benign nerve tumors into cancers
Researchers at UCLA's Jonsson Comprehensive Cancer Center showed for the first time that the loss or decreased expression of the tumor suppressor gene PTEN plays a central role in the malignant transformation of benign nerve tumors called neurofibromas into a malignant and extremely deadly form of sarcoma.
A potential new imaging agent for early diagnosis of most serious skin cancer
Scientists in Australia are reporting development and testing in laboratory animals of a potential new material for diagnosing malignant melanoma, the most serious form of skin cancer.
Combination of PET/CT tests can expedite diagnosis of lung cancer in a fast-track setting
Research published in the October 2009 issue of the Journal of Thoracic Oncology has found an effective combination of positron emission tomography (PET)/computed tomography (CT) (PET/CT) tests to diagnose lung cancer in a "fast-tracked" outpatient setting.
Molecular imaging holds promise for early intervention in common uterine cancer
A promising new molecular imaging technique may provide physicians and patients with a noninvasive way to learn more information about a type of cancer of the uterus lining called "endometrial carcinoma"-one of the most common malignant female tumors.
New genetic link between cardiac arrhythmias and thyroid dysfunction identified
Genes previously known to be essential to the coordinated, rhythmic electrical activity of cardiac muscle -- a healthy heartbeat -- have now also been found to play a key role in thyroid hormone (TH) biosynthesis, according to Weill Cornell Medical College researchers.
PET/CT scans may help detect recurring prostate cancer earlier
A new study published in the September issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET)/computer tomography (CT) scans with the imaging agent choline could detect recurring prostate cancer sooner than conventional imaging technologies in some patients who have had their prostates surgically removed.
Radiologists, medical physicists work to make imaging procedures safer
The Radiological Society of North America (RSNA) reaffirmed its commitment to patient safety today in responding to a study and accompanying perspective on radiation dose from medical imaging procedures in the New England Journal of Medicine (NEJM).
Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness
Researchers from Turku, Finland, have identified a blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
More Positron Emission Tomography Current Events and Positron Emission Tomography News Articles
 |
Positron Emission Tomography: Basic Sciences by Dale L. Bailey (Editor), David W. Townsend (Editor), Peter E. Valk (Editor), Michael N. Maisey (Editor) This book is a practical manual covering the basic science of Positron Emission Tomography (PET). In recent years, clinicians have taken an active interest in PET with huge ramifications in patient management. However, until recently, this subject area has largely been a realm of scientists. A significant part of the book describes the physics and technology behind the imaging detectors and techniques. It covers cyclotrons, PET instrumentation, radiochemistry, PET data acquisition and image formation, integration of structural and functional images, radiation dosimetry and protection, and applications especially in dedicated areas such as drug development, small animal scanning and gene expression imaging. This is to familiarize the reader with, and to give an understanding of the... |
 |
Positron Emission Tomography: Clinical Practice by Peter E. Valk (Editor), Dominique Delbeke (Editor), Dale L. Bailey (Editor), David W. Townsend (Editor), Michael N. Maisey (Editor) This text is based on the 2nd half of P.E. Valk et al's 2003 bestseller Positron Emission Tomography: Basic Science and Clinical Practice and deals with only the clinical research and applications. "Positron Emission Tomography: Clinical Practice" has 22 fully revised and updated chapters, enhanced by 6 completely new chapters. The abundance of new material makes this an essential volume for anyone training in, or practicing, Nuclear Medicine. The first chapters summarize the scientific aspects of PET and PET/CT. A chapter on normal variants in FDG PET imaging serves as an introduction to the clinical chapters which cover oncology applications and the impact of FDG PET/CT imaging in oncology, concluding with chapters on PET and PET/CT in cardiology, neurology, PET imaging of infectious... |
 |
Principles and Practice of PET and PET/CT (Ct Second Edition) by Richard L Wahl (Editor), Robert SB Beanlands (Editor) The definitive text by the foremost authorities on positron emission tomography (PET) has now been thoroughly revised to reflect the major alterations in PET technology and practice since the introduction of PET/CT scanners. Now titled Principles and Practice of PET and PET/CT, this Second Edition includes many PET/CT images and new chapters dealing with CT scanning and PET/CT image fusion. The major focus is on strategies to optimally integrate CT and PET to a "one-stop" diagnosis for cancer, heart disease, neurologic disorders, psychiatric disorders, infection, inflammation, and other conditions. |
 |
Principles and Practice of Positron Emission Tomography by Richard L Wahl (Author), Julia W Buchanan (Author) The Johns Hopkins Univ., Baltimore, MD. Presents a comprehensive guide to the way positron emission tomography works and how to use PET to enhance the care of patients. Provides the basic principles of the techniques used in the in vivo process. Contains detailed halftone images and photographs. Written in expanded-outline format. DNLM: Tomography, Emission-Computed--methods. |
 |
PET/CT: Essentials for Clinical Practice by Ronald B. Workman Jr. (Editor), R. Edward Coleman (Editor), Martin P. Sandler (Editor) This pocket guide is for all clinicians involved in the diagnosis, initial staging, and re-staging of malignancy who are interested in learning how to incorporate PET into clinical practice. It provides concise, coherent, and informative discussions that get to the heart of how to effectively use PET and PET/CT in patient management for a wide range of clinical conditions. Introductory chapters cover the fundamentals of PET imaging, including the basic science behind PET (instrumentation and radiopharmaceuticals), patient preparation, and logistical considerations. Current reimbursement issues are also addressed. The bulk of the guide then examines PET’s role in the management of patients afflicted with malignancies currently covered by the Centers for Medicare and Medicaid Services... |
 |
Positron Emission Tomography-Computed Tomography: A Disease-Oriented Approach by Elissa Kramer (Editor), Jane Ko MD (Editor), Fabio Ponzo MD (Editor), Karen Mourtzikos MD (Editor) Positron Emission Tomography Computed Tomography: A Disease-Oriented Approach offers Radiologists and Nuclear Medicine specialists a thorough understanding of the clinical application of PET-CT—a groundbreaking modality that provides a powerful fusion of imaging anatomy and metabolic function. Written with a disease-oriented approach, PET-CT examines understanding, using, and interpreting PET-CT imaging in clinical practice. Co-authored by experts in both PET and CT imaging, this text serves as an integrated review of the practical aspects of this new imaging modality while providing comprehensive and evidence-based coverage. This volume covers all clinical entities for which PET-CT can be utilized in today’s modern practice. Using an integrated... |
 |
Atlas of Clinical Positron Emission Tomography: Includes interactive DVD-ROM (Hodder Arnold Publication) by Sally F. Barrington (Author), Michael N. Maisey (Author), Richard L. Wahl (Author) Positron Emitron Tomography (PET) is now firmly established as an invaluable technique for diagnosing and monitoring disease. The second edition of this comprehensive clinical atlas will continue to present the combined experience of two of the world's leading PET centers as the technique has moved on from its formative years to gain established value in clinical practice. The book has been substantially rewritten to take account of the exciting developments that are occurring with the introduction of PET/CT, and new 'state-of-the-art' PET/CT images are presented. The new edition continues to be presented as a series of 'mini-lectures' carefully designed for rapid assimilation, illustrated by case histories in which high-quality illustrations are supplemented by clear concise teaching... |
 |
Basics of PET Imaging: Physics, Chemistry, and Regulations by Gopal B. Saha (Author) This book is an ideal text on PET imaging technology that focuses on the basics, such as physics, instrumentation, production of PET radionuclides and radiopharmaceuticals, and regulations affecting PET. The chapters are concise but comprehensive, making the topic easily understandable, and they are complete with reviews of pertinent basic science and lists of suggested reading. Practical tables and appendixes contain a wealth of valuable data, reflecting the bookÆs usefulness as a reference for nuclear medicine professionals, including physicians, residents, and technologists. The book also benefits technologists and residents preparing for board examinations because of its brevity and clarity of content. |
|
Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart by Michael E., Ph.D. Phelps (Author), John Mazziotta (Author), Heinrich R. Schelbert (Editor) | |
 |
Radiopharmaceuticals for Positron Emission Tomography - Methodological Aspects (Developments in Nuclear Medicine) by G. Stöcklin (Editor), V.W. Pike (Editor) Radiochemical methodology constitutes the most important base for the successful functioning of a PET group in the routine production and development of radiopharmaceuticals. Of the several hundred products which have been labelled with positron emitters during the past two decades about 35 are presently considered to be of major interest. The time for a state-of-the-art review is right, since this field has advanced over the past fifteen years to reach a level where guidelines can now be suggested. Chapters of this book deal with each of the main methodological aspects of the chemistry needed to develop an effective radiopharmaceutical, namely radionuclide production, automation and metabolite analysis. A further chapter on QA/QC is written by a broadly-based expert group and... |
| © 2009 BrightSurf.com |